{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:29:42Z","timestamp":1793690982823,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,19]]},"DOI":"10.7759\/cureus.56447","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T06:03:27Z","timestamp":1710828207000},"source":"Crossref","is-referenced-by-count":1,"title":["An Open-Label, Single-Arm, Multicenter, Observational Study Evaluating the Safety and Effectiveness of Akynzeo\u00ae in the Management of Chemotherapy-Induced Nausea and Vomiting in India"],"prefix":"10.7759","author":[{"given":"Chandrakanth","family":"MV","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boben","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanshyam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumant","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palanki S","family":"Dattatreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00400","article-title":"Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective","volume":"10","author":"Vaid AK","year":"2020","unstructured":"Vaid AK, Gupta S, Doval DC, et al.. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol. 2020, 10:400. 10.3389\/fonc.2020.00400","journal-title":"Front Oncol"},{"key":"ref2","article-title":"Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies","volume":"23","author":"Adel N","year":"2017","unstructured":"Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017, 23:S259-65.","journal-title":"Am J Manag Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4131-3","article-title":"CINV: still troubling patients after all these years","volume":"26","author":"Aapro M","year":"2018","unstructured":"Aapro M. CINV: still troubling patients after all these years. Support Care Cancer. 2018, 26:5-9. 10.1007\/s00520-018-4131-3","journal-title":"Support Care Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv138","article-title":"Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review","volume":"26","author":"Jordan K","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015, 26:1081-90. 10.1093\/annonc\/mdv138","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08342-1","article-title":"The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting","volume":"21","author":"Vaswani B","year":"2021","unstructured":"Vaswani B, Dattatreya PS, Bhagat S, Patil S, Barkate H. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting. BMC Cancer. 2021, 21:601. 10.1186\/s12885-021-08342-1","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3502-x","article-title":"NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron","volume":"25","author":"Aapro M","year":"2017","unstructured":"Aapro M, Karthaus M, Schwartzberg L, et al.. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer. 2017, 25:1127-35. 10.1007\/s00520-016-3502-x","journal-title":"Support Care Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"Gralla RJ","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, et al.. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014, 25:1333-9. 10.1093\/annonc\/mdu096","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh PJ","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, et al.. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014, 25:1340-6. 10.1093\/annonc\/mdu110","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2373-2","article-title":"Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries","volume":"23","author":"Hsieh RK","year":"2015","unstructured":"Hsieh RK, Chan A, Kim HK, et al.. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer. 2015, 23:263-72. 10.1007\/s00520-014-2373-2","journal-title":"Support Care Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","volume":"29","author":"Zhang L","year":"2018","unstructured":"Zhang L, Lu S, Feng J, et al.. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018, 29:452-8. 10.1093\/annonc\/mdx698","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S203634","article-title":"Management of chemotherapy-induced nausea and vomiting (CINV): a short review on the role of netupitant-palonosetron (NEPA)","volume":"15","author":"Lorusso V","year":"2020","unstructured":"Lorusso V, Russo A, Giotta F, Codega P. Management of chemotherapy-induced nausea and vomiting (CINV): a short review on the role of netupitant-palonosetron (NEPA). Core Evid. 2020, 15:21-9. 10.2147\/CE.S203634","journal-title":"Core Evid"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro M","year":"2014","unstructured":"Aapro M, Rugo H, Rossi G, et al.. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014, 25:1328-33. 10.1093\/annonc\/mdu101","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0187","article-title":"Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life","volume":"16","author":"Karthaus M","year":"2020","unstructured":"Karthaus M, Oskay-\u00d6zcelik G, W\u00fclfing P, et al.. Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life. Future Oncol. 2020, 16:939-53. 10.2217\/fon-2020-0187","journal-title":"Future Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.17925\/eoh.2010.06.02.14","article-title":"Treatment of chemotherapy-induced nausea in cancer patients","volume":"6","author":"Ryan JL","year":"2010","unstructured":"Ryan JL. Treatment of chemotherapy-induced nausea in cancer patients. Eur Oncol. 2010, 6:14-6. 10.17925\/eoh.2010.06.02.14","journal-title":"Eur Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000514891","article-title":"Quality of life effects of an oral fixed combination of netupitant and palonosetron in chemotherapy-induced nausea and vomiting prevention: real-world evidence in patients with breast cancer receiving anthracycline-cyclophosphamide-based chemotherapy","volume":"17","author":"Schilling J","year":"2022","unstructured":"Schilling J, Kurbacher CM, Hanusch C, et al.. Quality of life effects of an oral fixed combination of netupitant and palonosetron in chemotherapy-induced nausea and vomiting prevention: real-world evidence in patients with breast cancer receiving anthracycline-cyclophosphamide-based chemotherapy. Breast Care (Basel). 2022, 17:130-6. 10.1159\/000514891","journal-title":"Breast Care (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2174\/1568009622666220513094352","article-title":"Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice","volume":"22","author":"Aapro M","year":"2022","unstructured":"Aapro M, Jordan K, Scott\u00e9 F, Celio L, Karthaus M, Roeland E. Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice. Curr Cancer Drug Targets. 2022, 22:806-24. 10.2174\/1568009622666220513094352","journal-title":"Curr Cancer Drug Targets"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli S","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al.. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003, 97:3090-8. 10.1002\/cncr.11433","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095","article-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group","volume":"21","author":"Hesketh PJ","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, et al.. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003, 21:4112-9. 10.1200\/JCO.2003.01.095","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.7859","article-title":"Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE","volume":"29","author":"Grunberg S","year":"2011","unstructured":"Grunberg S, Chua D, Maru A, et al.. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011, 29:1495-501. 10.1200\/JCO.2010.31.7859","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr DG","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, et al.. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005, 23:2822-30. 10.1200\/JCO.2005.09.050","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.12.158","article-title":"Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial","volume":"8","author":"Zhang Z","year":"2020","unstructured":"Zhang Z, Yang Y, Lu P, et al.. Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial. Ann Transl Med. 2020, 8:234. 10.21037\/atm.2019.12.158","journal-title":"Ann Transl Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy169","article-title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy","volume":"29","author":"Schwartzberg L","year":"2018","unstructured":"Schwartzberg L, Roeland E, Andric Z, et al.. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018, 29:1535-40. 10.1093\/annonc\/mdy169","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0527","article-title":"Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy","volume":"25","author":"Schwartzberg L","year":"2020","unstructured":"Schwartzberg L, Navari R, Clark-Snow R, et al.. Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. Oncologist. 2020, 25:e589-97. 10.1634\/theoncologist.2019-0527","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/221763-an-open-label-single-arm-multicenter-observational-study-evaluating-the-safety-and-effectiveness-of-akynzeo-in-the-management-of-chemotherapy-induced-nausea-and-vomiting-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:04:53Z","timestamp":1793689493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/221763-an-open-label-single-arm-multicenter-observational-study-evaluating-the-safety-and-effectiveness-of-akynzeo-in-the-management-of-chemotherapy-induced-nausea-and-vomiting-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.56447","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}